Emerging Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Chronic Respiratory Diseases: An Overview of Recent Progress.

Emerging Therapeutic Potential of Mesenchymal Stem Cell-Derived Extracellular Vesicles in Chronic Respiratory Diseases: An Overview of Recent Progress.
复制标题

间充质干细胞来源的细胞外囊泡在慢性呼吸道疾病中的新兴治疗潜力:最新进展概述

DOI:
10.3389/fbioe.2022.845042
复制
发表时间:
2022
影响因子:
5.7
通讯作者:
Chen Y
Chen Y
中科院分区:
工程技术2区
文献类型:
--
作者:
Ma Y;Liu X;Long Y;Chen Y

文献摘要

参考文献

相似文献

间充质干细胞衍生的细胞外囊泡(MSC-EV)能够携带遗传物质和蛋白质物质以介导MSC与靶细胞之间的相互作用。近年来,MSC-EV在慢性呼吸系统疾病中的治疗作用受到越来越多的研究关注。本文就MSC-EV治疗慢性呼吸系统疾病的策略和机制进行综述。这篇综述表明,MSC-EV可能作为一种新的无细胞治疗慢性呼吸系统疾病,包括COPD,哮喘,肺纤维化和肺动脉高压。在目前慢性呼吸系统疾病的研究中,脐带和骨髓是MSC-EV的主要来源,脂肪组织、肺和诱导多能干细胞也被应用。用于治疗慢性呼吸道疾病的MSC-EV的分离方法包括超离心法、外泌体提取试剂盒和阴离子交换色谱法。肠内递送和静脉内给药是MSC-EV最广泛使用的途径。MSC-EV能够将microRNA和蛋白质转移到靶细胞,并进一步放大治疗效果。
Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are able to carry genetic and protein goods to mediate the interaction between MSCs and target cells. Recently, more and more researches have focused on the therapeutic role of MSC-EVs in chronic respiratory diseases. In this review, we summarize the cumulative strategies and mechanisms of MSC-EVs in treating chronic respiratory diseases. This review suggests that MSC-EVs may serve as a novel cell-free-based therapy for chronic respiratory diseases, including COPD, asthma, pulmonary fibrosis, and pulmonary arterial hypertension. In current studies of chronic respiratory diseases, umbilical cord and bone marrow are main sources of MSC-EVs, while adipose tissue, lung, and induced pluripotent stem cells are also applied. Isolation methods of MSC-EVs in treating chronic respiratory diseases involve ultracentrifugation, exosome extraction kits and anion-exchange chromatography. Intratracheal delivery and intravenous administration are the most widely used routes of MSC-EVs. MSC-EVs are able to transfer microRNAs and protein to target cells and further magnify the therapeutic effects.
DOI: 10.1097/cm9.0000000000001596
发表时间: 2021-06-15
影响因子: 6.1
作者:
Chen YT;Miao K;Zhou L;Xiong WN
通讯作者: Xiong WN
DOI: 10.1016/j.taap.2019.114788
发表时间: 2019-12-15
影响因子: 3.8
作者:
Maremanda, Krishna Prahlad;Sundar, Isaac Kirubakaran;Rahman, Irfan
通讯作者: Rahman, Irfan
DOI: 10.1165/rcmb.2019-0154oc
发表时间: 2020-05-01
影响因子: 6.4
作者:
Klinger, James R.;Pereira, Mandy;Liang, Olin D.
通讯作者: Liang, Olin D.
DOI: 10.1371/journal.pone.0148407
发表时间: 2016
期刊: PloS one
影响因子: 3.7
作者:
Lasda E;Parker R
通讯作者: Parker R
DOI: 10.1161/hypertensionaha.121.14596
发表时间: 2021-08
期刊: Hypertension (Dallas, Tex. : 1979)
影响因子: --
作者:
Eirin A;Lerman LO
通讯作者: Lerman LO